Intellia Therapeutics Says One Dose Of NEX-Z Shows Durable TTR Reductions Of At Least 90% Through Three Years
View all comments(0)
Sept 25 (Reuters) - Intellia Therapeutics Inc NTLA.O:
INTELLIA THERAPEUTICS ANNOUNCES POSITIVE LONGER-TERM PHASE 1 DATA FOR NEXIGURAN ZICLUMERAN (NEX-Z) IN PATIENTS WITH HEREDITARY TRANSTHYRETIN (ATTR) AMYLOIDOSIS WITH POLYNEUROPATHY
INTELLIA THERAPEUTICS INC - ONE DOSE OF NEX-Z SHOWS DURABLE TTR REDUCTIONS OF AT LEAST 90% THROUGH THREE YEARS
INTELLIA THERAPEUTICS INC - FAVORABLE SAFETY DATA WITH NO NEW DRUG-RELATED EVENTS
INTELLIA THERAPEUTICS INC - PHASE 3 MAGNITUDE-2 TRIAL ENROLLMENT EXPECTED BY FIRST HALF 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Copper Prices Near All-Time Highs. Citi: If Strait of Hormuz Is Unblocked, Price Will Rise to $15,000 by Year-End

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.